Phase III results of a single oral, 3-day oral, and 3-day iv/oral regimen of  casopitant, a novel neurikinin-1 (NK-1) receptor antagonist, for chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)

Jørn Herrstedt (Foredragsholder)

Aktivitet: Foredrag og mundtlige bidragForedrag og præsentationer i privat eller offentlig virksomhed

Periode26. jun. 2008
BegivenhedstitelInternational Symposium Supportive Care in Cancer
BegivenhedstypeKonference
Konferencenummer21
PlaceringHouston, USA